The study conducted at Center for the Early Detection of Breast Tumors at Medical City’s oncology teaching hospital carried 90 patients who participated in this study. The research was carried out between February 15, 2021, and July 20, 2021. The diagnosis was made by the consultant medical team using the triple assessment technique, which includes physical breast examination, ultrasonography, mammography, and fine needle aspiration cytology.
Women patients clasified into 3 groups (benign tumor, control and malignant tumor) benign B (34 women) divided in/to two sub groups such as (benign premenopausal age B1 (17) and benign postmenopausal age B2 (17) and malignant M (34), malignant premenopausal age M1 (17) and malignant postmenopausal age M2 (17), and control group C includes (11) premenopausal age C1 and (11) C2. An ELISA approach was used to measure the level of soluble PDL, PD L1, and CD8 expression in serum.
PD1 shows significant increase (p ≤ 0.05) in pre- and post-menopausal malignant groups M5, M6 when compared with C1, C2, B1, B2. PDL-1 levels were non-significant (p ≥ 0.05) in pre and postmenopausal control and benign groups (C1, C2, B1 and B2) while they were increased significantly (p ≤ 0.05) in M1, M2 in comparison with B2,C1,C2, B1. CD8 in the M1 increased significantly (p ≤ 0.05) when compere with group1, group 2, group bening1, group benign 2 and malignant 2.
Conclusions from the current study that the values of PD1and PDL1in pre and postmenopausal malignant women breast cancer showed an increase compere with the other groups, the levels of CD8+ increase in the premenopausal malignant breast cancer women in comparison with other groups.